- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.06. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.06. | MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements | 90 | GlobeNewswire (Europe) | NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan ("MEDIROM" or the "Company"), today announced that on... ► Artikel lesen | |
| MEDIROM HEALTHCARE TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 30.05. | MEDIROM Healthcare Technologies Inc.: Specific Health Guidance Service Utilizing the "Lav" Healthcare App: Surpassed 100 cumulative contracted companies and 10,000 cumulative supported individuals! | 1 | GlobeNewswire (USA) | ||
| 30.05. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.05. | MEDIROM Healthcare Technologies - ADS GAAP EPS of ¥28.52, revenue of ¥8.3B | 1 | Seeking Alpha | ||
| 20.05. | MEDIROM Healthcare Technologies Inc. Announces 22% Rise in Revenue and 20% Improvement in Earnings for 2024; Webcast to Discuss Financial Results to be held on May 21st, 2025 at 8:30 AM ET | 2 | GlobeNewswire (USA) | ||
| 20.05. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 19.05. | MEDIROM Healthcare Technologies Inc. to Host Webcast on May 21, 2025 at 8:30 AM ET to Discuss 2024 Financial Results | 1 | GlobeNewswire (USA) | ||
| 29.04. | Medirom Healthcare Technologies Inc. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 23.04. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.03. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.03. | MEDIROM Healthcare Technologies Inc. Announces New JPY350 Million (Approximately $2.4 Million) Unsecured Loan Financing | 276 | GlobeNewswire (Europe) | TOKYO, March 17, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the "Company" or "MEDIROM"), today announced that it... ► Artikel lesen | |
| 13.03. | MEDIROM Healthcare Technologies Inc.: MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs' Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million) | 2 | GlobeNewswire (USA) | ||
| 13.03. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.03. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.02. | MEDIROM Healthcare sees FY24 revenue to be about JPY8.2B | 1 | Seeking Alpha | ||
| 18.02. | MEDIROM Healthcare Technologies Inc. Announces Preliminary, Unaudited Financial Results for Full Year 2024 Under Japanese GAAP | 296 | GlobeNewswire (Europe) | NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the "Company"), today announced its preliminary, unaudited... ► Artikel lesen | |
| 18.02. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 29.01. | MEDIROM Healthcare Technologies Inc. Announces December 2024 Key Performance Indicators (KPIs) | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,094 | -3,09 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,745 | +3,33 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
| PING AN HEALTHCARE | 0,937 | -1,18 % | PA GOODDOCTOR (01833): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2025 | ||
| CO-DIAGNOSTICS | 0,240 | +1,69 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 1,092 | +1,68 % | Cytosorbents Corp: CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb-ATR | PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| VERU | 0,511 | +2,18 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
| VOLITIONRX | 0,835 | 0,00 % | VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., May 15, 2025 /PRNewswire/... ► Artikel lesen | |
| EKSO BIONICS | 3,280 | 0,00 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
| IMUNON | 0,665 | -2,21 % | Imunon, Inc.: IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 | ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism... ► Artikel lesen | |
| BEYOND AIR | 0,153 | +4,79 % | Beyond Air-Aktionäre genehmigen Reverse-Aktiensplit | ||
| AVINGER | 0,465 | -22,17 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| NOVACYT | 0,492 | +0,20 % | Novacyt S.A. - Result of AGM | ||
| AROVELLA THERAPEUTICS | 0,071 | +22,61 % | AROVELLA THERAPEUTICS LIMITED: Final Director's Interest Notice | ||
| SIEMENS HEALTHINEERS | 47,060 | +0,34 % | Neue 5,68% Aktienanleihe auf Siemens Healthineers | Düsseldorf (www.anleihencheck.de) - Die HSBC Trinkaus & Burkhardt AG, Düsseldorf, bietet ab dem 24. Juni 2025 eine neue Aktienanleihe (ISIN DE000HT69A65/ WKN HT69A6) auf die Aktie der Siemens Healthineers... ► Artikel lesen |
Das Unternehmen MEDIROM HEALTHCARE TECHNOLOGIES INC ADR kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDIROM HEALTHCARE TECHNOLOGIES INC ADR finden Sie auf Wallstreet Online.